BDSX Pemfailan SEC - Biodesix, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

CIK

1439725

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biodesix, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

August 7, 2025	EX-99.1	Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance Exhibit 99.1 Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, August 7, 2025 – Biodesix, Inc. (Nasdaq: BDSX), a l
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX,
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
May 30, 2025	EX-FILING FEES	Filing Fee Exhibit. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
May 30, 2025	S-8	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No.
May 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
May 13, 2025	EX-4.2	Second Amendment to Warrant Certificate, dated May 12, 2025, issued by the Company to Perceptive Credit Holdings IV, LP. Exhibit 4.2 Second Amendment to Warrant Certificate This Second Amendment to Warrant Certificate, dated as of May 12, 2025 (this “Amendment”), is entered into by and among Biodesix, Inc. a Delaware corporation (the “Company”) and Perceptive Credit Holdings IV, LP, a Delaware limited partnership (the “Holder”). Recitals Whereas, the Company issued to the Holder that certain Warrant Certificate, dat
May 13, 2025	EX-4.1	First Amendment to Warrant Certificate, dated May 12, 2025, issued by the Company to Perceptive Credit Holdings IV, LP. Exhibit 4.1 First Amendment to Warrant Certificate This First Amendment to Warrant Certificate, dated as of May 12, 2025 (this “Amendment”), is entered into by and among Biodesix, Inc. a Delaware corporation (the “Company”) and Perceptive Credit Holdings IV, LP, a Delaware limited partnership (the “Holder”). Recitals Whereas, the Company issued to the Holder that certain Warrant Certificate, dated
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX,
May 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I.
May 13, 2025	EX-99.1	Biodesix Announces First Quarter 2025 Results and Highlights Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guida Exhibit 99.1 Biodesix Announces First Quarter 2025 Results and Highlights Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, May 13, 2025 – Biodesix, Inc. (Nasdaq
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 17, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 15, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
April 17, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 28, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 24, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
March 3, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I
March 3, 2025	EX-10.36	Fifth Amendment to Credit Agreement and Guaranty, dated February 28, 2025, by and between the Company and Perceptive Credit Holdings IV, LP. Exhibit 10.36 Fifth Amendment to Credit Agreement and Guaranty This Fifth Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of February 28, 2025 (the “Fifth Amendment Effective Date”), by and among Biodesix, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings IV, LP, a Delaware l
March 3, 2025	EX-4.8	First Amendment to Warrant Certificate, dated February 28, 2025, issued by the Company to Perceptive Credit Holdings IV, LP. Exhibit 4.8 First Amendment to Warrant Certificate This First Amendment to Warrant Certificate, dated as of February 28, 2025 (this “Amendment”), is entered into by and among Biodesix, Inc. a Delaware corporation (the “Company”) and Perceptive Credit Holdings IV, LP, a Delaware limited partnership (the “Holder”). Recitals Whereas, the Company issued to the Holder that certain Warrant Certificate,
March 3, 2025	EX-99.1	Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, March 3, 2025 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions comp
March 3, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc.
March 3, 2025	EX-19.1	Policy Relating to Insider Trading. Exhibit 19.1 BIODESIX, INC. Insider Trading Policy Introduction This policy determines acceptable transactions in the securities of Biodesix, Inc. (the “Company” or “Biodesix”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publicly available (“inside information”
February 7, 2025	S-8	As filed with the Securities and Exchange Commission on February 7, 2025 As filed with the Securities and Exchange Commission on February 7, 2025 Registration No.
February 7, 2025	EX-FILING FEES	Filing Fee Exhibit. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biodesix, Inc.
January 10, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
January 10, 2025	EX-99.1	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) Grew full-year revenue to an estimated $71.3 million, an increase of 45% Exhibit 99.1 Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) Grew full-year revenue to an estimated $71.3 million, an increase of 45% LOUISVILLE, CO, January 10, 2025 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). Th
November 13, 2024	SC 13G/A	BDSX / Biodesix, Inc. / Life Sciences Alternative Funding LLC Passive Investment SC 13G/A 1 formsc13ga.htm United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share
November 12, 2024	424B5	Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282938 PROSPECTUS Up to $50,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC (“TD Cowen”) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregat
November 12, 2024	424B3	BIODESIX, INC. 62,202,399 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282939 PROSPECTUS BIODESIX, INC. 62,202,399 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus of up to an aggregate of 62,202,399 shares of our common stock, par value $0.001 per share. We are
November 7, 2024	CORRESP	[Signature Page Immediately Follows] CORRESP November 7, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Conlon Danberg Re: Acceleration Request for Biodesix, Inc. Registration Statement on Form S-3 (File No. 333-282939) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biodesix, Inc. (the “Company”)
November 7, 2024	CORRESP	[Signature Page Immediately Follows] CORRESP November 7, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Conlon Danberg Re: Acceleration Request for Biodesix, Inc. Registration Statement on Form S-3 (File No. 333-282938) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biodesix, Inc. (the “Company”)
November 1, 2024	S-3	As filed with the Securities and Exchange Commission on November 1, 2024. S-3 Table of Contents As filed with the Securities and Exchange Commission on November 1, 2024.
November 1, 2024	EX-1.2	Sales Agreement, dated as of November 1, 2024, between the Registrant and TD Securities (USA) LLC Exhibit 1.2 BIODESIX, INC. $50,000,000 SHARES OF COMMON STOCK SALES AGREEMENT November 1, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, NY 10017 Ladies and Gentlemen: Biodesix, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time duri
November 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODE
November 1, 2024	EX-99.1	Biodesix Announces Third Quarter 2024 Results and Highlights Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call Exhibit 99.1 Biodesix Announces Third Quarter 2024 Results and Highlights Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, CO, November 1, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions compan
November 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
November 1, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee
November 1, 2024	S-3	As filed with the Securities and Exchange Commission on November 1, 2024. S-3 Table of Contents As filed with the Securities and Exchange Commission on November 1, 2024.
November 1, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo
November 1, 2024	EX-10.1	Fourth Amendment to Credit Agreement and Guaranty, dated October 30, 2024, by and between the Company and Perceptive Credit Holdings IV, LP. Exhibit 10.1 Fourth Amendment to Credit Agreement and Guaranty This Fourth Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of October 30, 2024 (the “Fourth Amendment Effective Date”), by and among Biodesix, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings IV, LP, a Delaware
August 15, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
August 15, 2024	EX-99.1	Disclaimer This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ( Biodesix , “we” or the Company ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or s Exhibit 99.1 Corporate Presentation Biodesix is a blood-based lung diagnostic company addressing a large unmet need with limited competition © 2024 Biodesix, Inc. All rights reserved. 1 3Q24 Disclaimer This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ( Biodesix , “we” or the Company ) for informational purposes only and not for any other purpose. Nothin
August 7, 2024	424B5	Up to $50,000,000 BIODESIX, INC. Common Stock SUPPLEMENT NO. 2 DATED AUGUST 7, 2024 TO PROSPECTUS SUPPLEMENT DATED DECEMBER 22, 2021 Filed pursuant to Rule 424(b)(5) (to Prospectus dated November 29, 2021) Registration No. 333-261095 Up to $50,000,000 BIODESIX, INC. Common Stock This Supplement No. 2 to the Prospectus Supplement (this “Supplement No. 2”) supplements and amends the Prospectus Supplement dated December 22, 2021, as supplemented
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
August 7, 2024	EX-10.1	Second Amendment to Supply Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 22, 2024. Exhibit 10.1 SECOND AMENDMENT TO THE NON-EXCLUSIVE LICENSE AGREEMENT This second amendment (“Amendment”) is effective May 22, 2024 (“Amendment Effective Date”), and is made pursuant to the Non-Exclusive License Agreement dated August 1, 2019, as amended (“Agreement”) by and between BIO-RAD LABORATORIES, INC., having an address at 1000 Alfred Nobel Drive, Hercules, California 94547 (“Bio-Rad”) and
August 7, 2024	EX-99.1	Biodesix Announces Second Quarter 2024 Results and Highlights Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from Exhibit 99.1 Biodesix Announces Second Quarter 2024 Results and Highlights Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and 38% over Q2 2023; Conference C
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX,
June 24, 2024	SC 13G	BDSX / Biodesix, Inc. / Telemark Asset Management, LLC - FORM 13G BIODESIX Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 4)* Biodesix, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) (Date of Event Which Requ
June 24, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on the Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Biodesix, Inc. is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigne
June 5, 2024	424B3	BIODESIX, INC. 30,434,280 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278881 PROSPECTUS BIODESIX, INC. 30,434,280 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus of up to 30,434,280 shares of Common Stock (the “Private Placement Conversion Shares”) issuable upo
May 31, 2024	CORRESP	[Signature Page Immediately Follows] May 31, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jane Park Re: Acceleration Request for Biodesix, Inc. Registration Statement on Form S-1 (File No. 333-278881) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biodesix, Inc. (the “Company”), hereby reques
May 24, 2024	CORRESP	* * * * SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SUITE 2000 SAN FRANCISCO, CA 94104 +1 415 772 1200 +1 415 772 7400 FAX AMERICA • ASIA PACIFIC • EUROPE May 24, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 24, 2024	S-1/A	As filed with the Securities and Exchange Commission on May 24, 2024. Table of Contents As filed with the Securities and Exchange Commission on May 24, 2024.
May 23, 2024	SC 13D/A	BDSX / Biodesix, Inc. / SCHULER JACK W - SC 13D/A Activist Investment SC 13D/A 1 ef20029870sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 Tri-State International, Suite 125 Lincolnshire, Illinois 60069
May 23, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
May 23, 2024	SC 13D/A	BDSX / Biodesix, Inc. / Kennedy Lawrence T. Jr - SC 13D/A Activist Investment SC 13D/A 1 ef20029871sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Lawrence T. Kennedy, Jr. 1700 Madison Road, Suite 200 Cincinnati, OH 45206 (513) 729
May 13, 2024	SC 13G	BDSX / Biodesix, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) April 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
May 13, 2024	EX-99.1	AGREEMENT EX-99.1 2 d745978dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: May 13, 2024 P
May 8, 2024	EX-99.1	Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management First quarter 2024 Total Revenue of $14.8 million, a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lu Exhibit 99.1 Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management First quarter 2024 Total Revenue of $14.8 million, a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume; First quarter 2024 gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth qua
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I.R
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX,
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 23, 2024	EX-10.42	Form of Executive Severance and Change in Control Agreement, dated April 23, 2024 by and among the Company and each of its executive officers. Exhibit 10.42 Form of Agreement BIODESIX, INC. EXECUTIVE SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Executive Severance and Change in Control Agreement (“Agreement”) is made and entered into as of this • day of •, • (the “Effective Date”), by and between Biodesix, Inc. (the “Company”) and • (the “Executive”). WHEREAS, the Board has approved the Company entering into executive severance and cha
April 23, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry
April 23, 2024	S-1	As filed with the Securities and Exchange Commission on April 23, 2024. Table of Contents As filed with the Securities and Exchange Commission on April 23, 2024.
April 16, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 9, 2024	SC 13D/A	BDSX / Biodesix, Inc. / Strobeck Matthew - SC 13D/A Activist Investment SC 13D/A 1 ef20026517sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack Trottier 688 Pine Street Burlington, VT 05401 (802) 923-3826 (Name, Address and
April 9, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 5, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I
April 9, 2024	EX-10.1	Securities Purchase Agreement, dated as of April 5, 2024 between Biodesix, Inc. and certain of the Investors (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on April 9, 2024). Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT BY AND AMONG BIODESIX, INC., AND THE PURCHASERS AS SET FORTH HEREIN APRIL 5, 2024 TABLE OF CONTENTS 1. Definitions 2 2. Purchase and Sale of Securities 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 5 3.1 Organization and Power; No Subsidiaries 5 3.2 Capitalization 6 3.3 Registration R
April 9, 2024	EX-99.1	Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement Exhibit 99.1 Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement LOUISVILLE, CO, April 5, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $
April 9, 2024	EX-10.2	Securities Purchase Agreement, dated as of April 5, 2024 between Biodesix, Inc. and certain members of management, certain of its directors and funds affiliated with those directors (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on April 9, 2024). Exhibit 10.2 Execution Version SECURITIES PURCHASE AGREEMENT BY AND AMONG BIODESIX, INC., AND THE PURCHASERS AS SET FORTH HEREIN APRIL 5, 2024 TABLE OF CONTENTS 1. Definitions 2 2. Purchase and Sale of Securities 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 5 3.1 Organization and Power; No Subsidiaries 5 3.2 Capitalization 6 3.3 Registration Rights 6 3.4
April 9, 2024	EX-3.1	Certificate of Designations of Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on April 9, 2024). Exhibit 3.1 BIODESIX, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Biodesix, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board of Dir
April 9, 2024	SC 13D/A	BDSX / Biodesix, Inc. / SCHULER JACK W - SC 13D/A Activist Investment SC 13D/A 1 ef20026519sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 Tri-State International, Suite 125 Lincolnshire, Illinois 60069
April 9, 2024	EX-1.1	Underwriting Agreement, dated April 5, 2024, by and among Biodesix, Inc. and TD Securities (USA) LLC, William Blair & Company, L.L.C. and Canaccord Genuity LLC Exhibit 1.1 Execution Version 17,391,832 Shares BIODESIX, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT April 5, 2024 April 5, 2024 TD Securities (USA) LLC William Blair & Company, L.L.C. Canaccord Genuity LLC As Representatives of the several Underwriters named in Schedule I hereto c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 c/o William Blair &
April 9, 2024	SC 13D/A	BDSX / Biodesix, Inc. / Kennedy Lawrence T. Jr - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Arthur McMahon, III, Esq. Taft Stettinius & Hollister LLP 425 Walnut Street, Suite 1800 Cincinnati, OH 45202 (513) 357-9607 (
April 9, 2024	EX-10.3	Registration Rights Agreement, dated as of April 5, 2024 between Biodesix, Inc. and the Investors (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the SEC on April 9, 2024). Exhibit 10.3 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 5, 2024, is entered into by and among Biodesix, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized t
April 9, 2024	SC 13D/A	BDSX / Biodesix, Inc. / PATIENCE JOHN - SC 13D/A Activist Investment SC 13D/A 1 ef20026515sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) John Patience c/o Biodesix, Inc. 919 West Dillon Rd Louisville, Colorado 80027 (520)
April 5, 2024	424B5	17,391,832 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-261095 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 29, 2021) 17,391,832 Shares Common Stock We are offering 17,391,832 shares of our common stock.
April 5, 2024	424B5	BIODESIX, INC. Common Stock SUPPLEMENT NO. 1 DATED APRIL 5, 2024 TO PROSPECTUS SUPPLEMENT DATED DECEMBER 22, 2021 Filed pursuant to Rule 424(b)(5) (to Prospectus dated November 29, 2021) Registration No. 333-261095 BIODESIX, INC. Common Stock This Supplement No. 1 to Prospectus Supplement (this “Supplement”) supplements and amends the Prospectus Supplement dated December 22, 2021 (the “Prospectus Supplement”). This Supplemen
March 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc.
March 1, 2024	EX-97.1	Policy Relating to Recovery of Erroneously Award Compensation. Exhibit 97.1 Biodesix, Inc. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Compensation Committee (the “Committee”) of Biodesix, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. This Polic
March 1, 2024	EX-10.35	Third Amendment to Credit Agreement and Guaranty, dated February 29, 2024, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2024). Exhibit 10.35 Third Amendment to Credit Agreement and Guaranty This Third Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of February 29, 2024 (the “Third Amendment Effective Date”), by and among Biodesix, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings IV, LP, a Delaware l
March 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2024 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I
March 1, 2024	EX-10.34	Limited Waiver, dated February 14, 2024, by and between Biodesix, Inc. and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2024). Exhibit 10.34 Limited Waiver This Limited Waiver, dated as of February 14, 2024 (this “Waiver”), is entered into by and among BIODESIX, INC., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and PERCEPTIVE CREDIT HOLDINGS IV, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and
March 1, 2024	EX-99.1	Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth; Ongoing improvement in gross profit margin with achievement of 77% in fourth quarter 2023, up 11 points over four
February 7, 2024	SC 13G/A	BDSX / Biodesix, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 BioDesix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 09075X108 (CUSIP Number) January, 24, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
February 2, 2024	EX-FILING FEES	Filing Fee Exhibit. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biodesix, Inc.
February 2, 2024	S-8	As filed with the Securities and Exchange Commission on February 2, 2024 As filed with the Securities and Exchange Commission on February 2, 2024 Registration No.
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 15, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 15, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODE
November 7, 2023	EX-99.1	Biodesix Announces Third Quarter 2023 Results and Highlights Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit margin of 76% versus 67% for t Exhibit 99.1 Biodesix Announces Third Quarter 2023 Results and Highlights Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit margin of 76% versus 67% for the third quarter 2022 and 73% for the second quarter of 2023; Net loss, which includes certain non-cash items, of $10.9 million improved
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
August 11, 2023	SC 13D/A	BDSX / Biodesix Inc / SCHULER JACK W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, Address and Telephone Number
August 7, 2023	EX-10.1	Form of Subscription Agreement, dated August 3, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2023). Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into this 3rd day of August 2023, by and between Biodesix, Inc., a Delaware corporation (the “Issuer”), and the undersigned (“Subscriber” or “you”). WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer’s common stock, $0.001 par value p
August 7, 2023	SC 13D/A	BDSX / Biodesix Inc / PATIENCE JOHN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) John Patience c/o Biodesix, Inc. 2970 Wilderness Place, Suite 100 Boulder, Colorado 80301 (520) 365-3100 (Name, Address and T
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX,
August 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
August 7, 2023	EX-10.2	Second Amendment to Credit Agreement and Guaranty, dated August 4, 2023, by and among the Company and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2023). Exhibit 10.2 Second Amendment to Credit Agreement and Guaranty This Second Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of August 4, 2023 (the “Second Amendment Effective Date”), by and among Biodesix, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings IV, LP, a Delaware li
August 7, 2023	EX-99.1	Biodesix Announces Second Quarter 2023 Results and Highlights Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit Exhibit 99.1 Biodesix Announces Second Quarter 2023 Results and Highlights Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit margin of 73% versus 64% for the second quarter 2022 and 65% for the first quarter 2023; Revenue continues to track to 2023 full year gui
August 7, 2023	SC 13D/A	BDSX / Biodesix Inc / Kennedy Lawrence T. Jr - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Arthur McMahon, III, Esq. Taft Stettinius & Hollister LLP 425 Walnut Street, Suite 1800 Cincinnati, OH 45202 (513) 357-9607 (
July 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 24, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 24, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
July 26, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODESIX, INC. (Name of Subject Company (Issuer) SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODESIX, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Nu
July 3, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODESIX, INC. (Name of Subject Company (Issuer) SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODESIX, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Nu
July 3, 2023	CORRESP	* * * * SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SUITE 2000 SAN FRANCISCO, CA 94104 +1 415 772 1200 +1 415 772 7400 FAX AMERICA • ASIA PACIFIC • EUROPE July 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 23, 2023	EX-99.A1A	Offer to Exchange Eligible Options for New Options, dated June 23, 2023 EX-99.(a)(1)(A) Exhibit (a)(1)(A) BIODESIX, INC. 2970 Wilderness Place, Suite 100 Boulder, Colorado 80301 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS JUNE 23, 2023 BIODESIX, INC. SUMMARY TERM SHEET—OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS This offer and withdrawal rights will expire at 10:00 p.m., Mountain Time, on July 24, 2023, unless extended By this Offer to Exchange
June 23, 2023	EX-99.A1I	Form of Email Notice Regarding Rejection of Options for Exchange Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: BIODESIX, INC.
June 23, 2023	EX-99.A1B	Form of Announcement Email to Eligible Holders Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE HOLDERS Subject: BIODESIX, INC.
June 23, 2023	EX-99.A1J	Form of Expiration Notice Email Exhibit (a)(1)(J) FORM OF EXPIRATION NOTICE EMAIL From: BIODESIX, INC. Re: Expiration of the Exchange Offer The Exchange Offer described in the Offer to Exchange Eligible Options for New Options, dated June 23, 2023 (the “Offer Documents”), has expired, and no additional Election Forms or Notices of Withdrawal may be submitted. If you are an Eligible Holder and delivered a properly completed and s
June 23, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Schedule TO (Form Type) Biodesix, Inc.
June 23, 2023	EX-99.A1H	Form of Email to Eligible Holders Confirming Acceptance of Eligible Options Exhibit (a)(1)(H) FORM OF EMAIL TO ELIGIBLE HOLDERS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS From: BIODESIX, INC.
June 23, 2023	EX-99.A1F	Form of Email Confirming Receipt of Notice of Withdrawal of Election Form Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: BIODESIX, INC.
June 23, 2023	EX-99.A1D	Notice of Withdrawal of Election Form Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by BIODESIX, INC.
June 23, 2023	EX-99.A1G	Form of Reminder Email to Eligible Holders Regarding the Expiration of the Exchange Offer Exhibit (a)(1)(G) FORM OF REMINDER EMAIL TO ELIGIBLE HOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: BIODESIX, INC.
June 23, 2023	EX-99.A1C	Election Form Exhibit (a)(1)(C) BIODESIX, INC. 2970 WILDERNESS PLACE, SUITE 100 BOULDER, COLORADO 80301 OPTION EXCHANGE—ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 P.M., MOUNTAIN TIME, ON MONDAY, JULY 24, 2023, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the documents that make up this tender offer, including (1) the Offer to Exchange E
June 23, 2023	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODESIX, INC. (Name of Subject Company (Issuer) and Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIODESIX, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number of Class of
June 23, 2023	EX-99.A1E	Form of Email Confirming Receipt of Election Form EX-99.01(a)(1)(E) Exhibit (a)(1)(E) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION FORM From: BIODESIX, INC. Re: Confirmation of Receipt of Election Form This message confirms that BIODESIX, INC. (“Biodesix”) has received your Election Form. This confirmation should not, however, be construed to imply that the Election Form you submitted has been properly completed or signed or that we have accepted
June 23, 2023	EX-99.A1L	Stock Option Exchange Program Presentation EX-99.(a)(1)(L) Option Exchange Program June 27, 2023 Exhibit (a)(1)(L) Why are we doing a stock option exchange? Stock options are an important part of the long-term incentive compensation offered to our employees Because the price of our common stock has decreased, many options are “under water” = stock option exercise price exceeds the current market price of our common stock Many options have
June 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 23, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 23, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
May 11, 2023	EX-10.3	First Amendment to Credit Agreement and Guaranty, dated May 10, 2023, by and among the Company and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023). Exhibit 10.3 First Amendment to Credit Agreement and Guaranty This First Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of May 10, 2023 (the “First Amendment Effective Date”), by and among Biodesix, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings IV, LP, a Delaware limited
May 11, 2023	EX-4.1	Warrant to Purchase Stock, dated May 10, 2023, issued by the Company to Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023). Exhibit 4.1 WARRANT certificate THIS WARRANT certificate AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT certificate HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I.
May 11, 2023	EX-10.2	De Soto Amendment to Commercial Lease Agreement, effective April 4, 2023, by and between Biodesix, Inc. and De Soto Investments, LLC (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023). Exhibit 10.2 AMENDMENT TO COMMERCIAL LEASE AGREEMENT This Amendment and Extension of Commercial Lease Agreement (this "Amendment"), entered into this 3rd day of March 2023 by and between DeSoto Investments, LLC (the "Landlord") and Biodesix Inc (the ''Tenant"). RECITALS: A. Landlord and Tenant have entered into that Commercial Lease Agreement dated November 1, 2020 (signed date) which is the "Leas
May 11, 2023	EX-10.1	Limited Waiver, dated April 7, 2023, by and between Biodesix, Inc. and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023). Exhibit 10.1 Limited Waiver This Limited Waiver, dated as of April 7, 2023 (this “Waiver”), is entered into by and among Biodesix, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings IV, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assi
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX,
May 11, 2023	EX-99.1	Biodesix Announces First Quarter 2023 Results and Highlights First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; C EX-99.1 2 bdsx-ex991.htm EX-99.1 Exhibit 99.1 Biodesix Announces First Quarter 2023 Results and Highlights First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; Conference Call and Webcast Today at 4:30 p.m. ET BOULDER, CO, May 11, 2023 – Biodesix, Inc. (Nasdaq: BDS
April 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ F DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 12, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ F DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 31, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ F PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 21, 2023	SC 13G	BDSX / Biodesix Inc / HIRSCHMAN ORIN Passive Investment UNITED STATE SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BioDesix, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 09075X108 (CUSIP Number) November 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
March 6, 2023	EX-10	Amendment No. 2 to the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.8.3 to the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023). Exhibit 10.8.3 Amendment Number Two To The Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan Whereas, Biodesix, Inc., a Delaware corporation (the “Company”) heretofore has adopted and maintains the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (the “Plan”), a subplan of the Biodesix, Inc. 2020 Equity Incentive Plan (the “Equity Incentive Plan”) to provide certain designated e
March 6, 2023	EX-99	Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively 2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range represents growth in excess of 60
March 6, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc.
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 6, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 6, 2023 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I
February 2, 2023	S-8	As filed with the Securities and Exchange Commission on February 2, 2023 S-8 As filed with the Securities and Exchange Commission on February 2, 2023 Registration No.
February 2, 2023	EX-FILING FEES	Filing Fee Exhibit. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
January 13, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 brhc10046665ex99-1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the common stock of Biodesix, Inc. dated as of January 13, 2023 is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with t
January 13, 2023	SC 13D	BDSX / Biodesix Inc / Kennedy Lawrence T. Jr - SC 13D Activist Investment SC 13D 1 brhc10046665sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Arthur McMahon, III, Esq. Taft Stettinius & Hollister LLP 425 Walnut Street, Suite 1800
December 16, 2022	EX-99.1	Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors Exhibit 99.1 Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors Boulder, CO.-(BUSINESS WIRE)-December 16, 2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company?s Board of Directors (Board) and Audit Committee of the
December 16, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
December 1, 2022	EX-99.1	Exhibit 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the common stock of Biodesix, Inc.
December 1, 2022	SC 13D	BDSX / Biodesix Inc / PATIENCE JOHN - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) John Patience c/o Biodesix, Inc. 2970 Wilderness Place, Suite 100 Boulder, Colorado 80301 (520) 365-3100 (Name, Address and Te
November 30, 2022	SC 13G/A	BDSX / Biodesix Inc / Kennedy Lawrence T. Jr - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea169471-13ga3kennedybiode.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3)* Under the Securities Exchange Act of 1934 Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Arthur McMahon, III, Esq. Taft Stettinius & Holli
November 23, 2022	SC 13D/A	BDSX / Biodesix Inc / SCHULER JACK W - SC 13D/A Activist Investment SC 13D/A 1 brhc10044588sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 88
November 23, 2022	SC 13D/A	BDSX / Biodesix Inc / Strobeck Matthew - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Richard McCormick 688 Pine Street Burlington, VT 05401 (802) 923-3826 (Name, Address and Telephone Number of Person Authorize
November 23, 2022	SC 13G/A	BDSX / Biodesix Inc / Manlia Ltd - SC 13G/A Passive Investment SC 13G/A 1 brhc10044591sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIODESIX, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) November 21, 2022 (Date of Event which Requires Filing of this Statement) Check th
November 21, 2022	EX-10.2	Security Agreement, dated as of November 21, 2022, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022). Exhibit 10.2 Executed Version Security Agreement Dated as of November 21, 2022 among Biodesix, Inc., as Grantor, The Other Grantors from Time to Time Party hereto and Perceptive Credit Holdings IV, LP, as Administrative Agent Table of Contents SECTION HEADING PAGE SECTION 1. Definitions, Etc. 1 Section 1.01. Certain Uniform Commercial Code Terms 1 Section 1.02. Additional Definitions 1 Section 1.0
November 21, 2022	EX-4.2	Warrant to Purchase Stock, dated November 21, 2022, issued by the Company to Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 4.2 in the Company's current report on Form 8-K filed with the SEC on November 21, 2022). EX-4.2 3 bdsx-ex42.htm EX-4.2 Exhibit 4.2 Executed Version WARRANT certificate THIS WARRANT certificate AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT certificate HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TR
November 21, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
November 21, 2022	EX-99.3	Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock EX-99.3 10 bdsx-ex993.htm EX-99.3 Exhibit 99.3 Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock BOULDER, CO, November 16, 2022 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the pu
November 21, 2022	EX-99.1	Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million $30 million initial funding $20 million in future revenue milestone-based funding Strengthens balance sheet and extends runway with five-year interes Exhibit 99.1 Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million $30 million initial funding $20 million in future revenue milestone-based funding Strengthens balance sheet and extends runway with five-year interest only period BOULDER, CO, November 16, 2022 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a f
November 21, 2022	EX-10.1	Credit Agreement and Guaranty, dated as of November 16, 2022, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022). Exhibit 10.1 Execution Version Credit Agreement and Guaranty dated as of November 16, 2022 among Biodesix, Inc., as the Borrower, The Guarantors from Time to Time Party hereto, as Guarantors, The Lenders from Time to Time Party hereto, as Lenders, and Perceptive Credit Holdings IV, LP, as the Administrative Agent and as a Lender $50,000,000 Table of Contents Section Heading Page Article I Definiti
November 21, 2022	EX-10.3	Form of Subscription Agreement, dated November 21, 2022 (incorporated by reference to Exhibit 10.3 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022). Exhibit 10.3 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into this 21st day of November, 2022, by and between Biodesix, Inc., a Delaware corporation (the “Issuer”), and the undersigned (“Subscriber” or “you”). WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer’s common stock, $0.001 par val
November 21, 2022	EX-1.1	Underwriting Agreement, dated November 16, 2022, between Biodesix, Inc. and William Blair & Company, L.L.C. Exhibit 1.1 Executed Version 30,500,000 Shares BIODESIX, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT November 16, 2022 November 16, 2022 William Blair & Company, L.L.C. As Representative of the several Underwriters named in Schedule I hereto c/o William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Biodesix, Inc., a Delaware
November 21, 2022	EX-99.4	Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares Exhibit 99.4 Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares BOULDER, CO, November 21, 2022 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public
November 21, 2022	EX-99.2	Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock Exhibit 99.2 Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock BOULDER, CO, November 16, 2022 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease,, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts a
November 18, 2022	424B5	30,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-261095 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 29, 2021) 30,500,000 Shares Common Stock We are offering 30,500,000 shares of our common stock.
November 16, 2022	424B5	SUBJECT TO COMPLETION, DATED NOVEMBER 16, 2022 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-261095 The information in this preliminary prospectus supplement is not complete and may be changed.
November 3, 2022	EX-99.1	Biodesix Announces Third Quarter 2022 Results and Highlights Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Exhibit 99.1 Biodesix Announces Third Quarter 2022 Results and Highlights Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio; Conference Call and Webcast Today at
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC.
November 3, 2022	EX-10.1	Consent and Fourth Amendment to Loan and Security Agreement Exhibit 10.1 CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of September 30, 2022, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and BIODESIX, INC., a Delaware corporation (?Borrower?). Recitals A. Bank and Borrower have entered into that certain Loan and Secu
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
October 11, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
October 11, 2022	EX-99.1	Biodesix Announces Preliminary Revenue for Third Quarter 2022 Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Exhibit 99.1 Biodesix Announces Preliminary Revenue for Third Quarter 2022 Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Boulder, CO, October 11, 2022- Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report third quarter 2022 to
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC.
August 4, 2022	EX-10.1	Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022). Exhibit 10.1 Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan 1. Purposes. The purpose of the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (the ?Plan?) is to provide certain designated employees of Biodesix, Inc., a Delaware corporation (the ?Company?), or its subsidiaries with the opportunity to receive a portion of their annual cash bonus in the form of a Nonstatutory Sto
August 4, 2022	EX-10.2	Amendment No. 1 to the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022). Exhibit 10.2 Amendment Number One To The Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan Whereas, Biodesix, Inc., a Delaware corporation (the ?Company?) heretofore has adopted and maintains the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (the ?Plan?), a subplan of the Biodesix, Inc. 2020 Equity Incentive Plan (the ?Equity Incentive Plan?) to provide certain designated emp
August 4, 2022	EX-99.1	Biodesix Announces Second Quarter 2022 Results and Highlights Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announce Exhibit 99.1 Biodesix Announces Second Quarter 2022 Results and Highlights Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT? Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and Bio-Rad); Reaffirm 2022 revenue ou
June 15, 2022	CORRESP	[Signature Page Immediately Follows] June 15, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Christine Westbrook Re: Acceleration Request for Biodesix, Inc. Registration Statement on Form S-3 (File No. 333-265448) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biodesix, Inc. (the ?Company?), here
June 6, 2022	S-8	As filed with the Securities and Exchange Commission on June 6, 2022 As filed with the Securities and Exchange Commission on June 6, 2022 Registration No.
June 6, 2022	S-3	As filed with the Securities and Exchange Commission on June 6, 2022. Table of Contents As filed with the Securities and Exchange Commission on June 6, 2022.
June 6, 2022	EX-FILING FEES	Filing Fee Exhibit. EX-FILING FEES 4 d359578dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amou
June 6, 2022	EX-FILING FEES	Filing Fee Exhibit. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biodesix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
May 25, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
May 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC.
May 11, 2022	EX-10.2	First Amendment to Lease Agreement by and between Centennial Valley Properties I, LLC and Biodesix, Inc. dated March 11, 2022 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022). Exhibit 10.2 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (SINGLE TENANT ? NNN) (this "First Amendment") is made and entered into this 11th day of March, 2022 (the "First Amendment Date"), by and between Centennial Valley Properties I, LLC, a Colorado limited liability company ("Landlord"), and Biodesix, Inc., a Delaware corporation ("Tenant"). RECITALS A. Landlord an
May 11, 2022	EX-10.8	Secured Convertible Promissory Note #1 by and between Streeterville Capital LLC and Biodesix, Inc. dated May 9, 2022. Exhibit 10.8 For purposes of sections 1272, 1273, and 1275 of the Internal Revenue Code of 1986, as amended, this note is being issued with an original issue discount. Borrower agrees to provide promptly to the holder of this Note, upon written request, the issue price, amount of original issue discount, issue date, and yield to maturity. Any such written request should be made pursuant to Section
May 11, 2022	EX-99.1	Biodesix Announces First Quarter 2022 Results and Highlights First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position through an additional $27.4 mill Exhibit 99.1 Biodesix Announces First Quarter 2022 Results and Highlights First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position through an additional $27.4 million in debt and equity funding during second quarter 2022; Conference Call and Webcast Today at 8:00 a.m. ET BOULDER, CO, May 11, 2022 ?
May 11, 2022	EX-10.7	Secured Purchase Agreement by and between Streeterville Capital LLC and Biodesix, Inc. dated May 9, 2022 (incorporated by reference to Exhibit 10.7 to the Company's Form 10-Q filed with the SEC on May 11, 2022) Exhibit 10.7 Securities Purchase Agreement This Securities Purchase Agreement (this ?Agreement?), dated as of May 9, 2022, is entered into by and between Biodesix, Inc., a Delaware corporation (?Company?), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and delivering this Agreement in reliance upon
May 11, 2022	EX-10.1	Lease agreement by and between Centennial Valley Properties I, LLC and Biodesix, Inc. dated March 11, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022). Exhibit 10.1 LEASE AGREEMENT (SINGLE TENANT ? NNN) by and between Centennial Valley Properties I, LLC ?Landlord? and Biodesix, Inc. ?Tenant? TABLE OF CONTENTS PAGE Article I BASIC PROVISIONS AND CERTAIN DEFINITIONS 1 ARTICLE II GRANTING CLAUSE 3 ARTICLE III ACCEPTANCE AND DELIVERY OF PREMISES; SUBDIVISION OF PREMISES 4 ARTICLE IV PERMITTED USE 5 ARTICLE V HAZARDOUS MATERIALS 6 ARTICLE VI TENANT'S
May 11, 2022	EX-10.6	Amendment No. 3 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.6 to the Company's Form 10-Q filed with the SEC on May 11, 2022). Exhibit 10.6 AMENDMENT NO. 3 TO ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATION This Amendment No. 3 to Asset Purchase Agreement and Plan of Reorganization (this ?Amendment?), is made and entered into as of April 7, 2022, and amends that certain Asset Purchase Agreement and Plan of Reorganization, dated June 30, 2018 (the ?Original Agreement?), by and among Biodesix, Inc. (the ?Company?); Inte
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I.
April 18, 2022	SC 13D	BDSX / Biodesix Inc / Strobeck Matthew - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Richard McCormick 688 Pine Street Burlington, VT 05401 (802) 923-3826 (Name, Address and Telephone Number of Person Authorized
April 12, 2022	SC 13G/A	BDSX / Biodesix Inc / Kennedy Lawrence T. Jr - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2)* Under the Securities Exchange Act of 1934 Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Arthur McMahon, III, Esq. Taft Stettinius & Hollister LLP 425 Walnut Street, Suite 1800 Cincinnati, OH 45202 (513) 357-9607
April 11, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 7, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I
April 11, 2022	SC 13D/A	BDSX / Biodesix Inc / SCHULER JACK W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, Address and Telephone Number
April 11, 2022	EX-10.1	Form of Subscription Agreement with resale registration rights provision, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022). Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into this 7th day of April 2022, by and between Biodesix, Inc., a Delaware corporation (the ?Issuer?), and the undersigned (?Subscriber? or ?you?). WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer?s common stock, $0.001 par value pe
April 11, 2022	EX-10.2	Form of Subscription Agreement without registration rights, entered by the three members of our Board of Directors, dated April 7, 2022 (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022). Exhibit 10.2 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into this 7th day of April 2022, by and between Biodesix, Inc., a Delaware corporation (the ?Issuer?), and the undersigned (?Subscriber? or ?you?). WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer?s common stock, $0.001 par value pe
April 11, 2022	EX-10.3	Consent and Third Amendment to Loan and Security Agreement Exhibit 10.3 CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of April 7, 2022, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and BIODESIX, INC., a Delaware corporation (?Borrower?). RECITALS A. Bank and Borrower have entered into that certain Loan and Security Ag
April 11, 2022	EX-99.1	Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $11.7 million in Common Shares Sold Under a Private Placement Third Amendment to 2021 Term Loan Provides Additional Financial Flexibility for Growth Exhibit 99.1 Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $11.7 million in Common Shares Sold Under a Private Placement Third Amendment to 2021 Term Loan Provides Additional Financial Flexibility for Growth BOULDER, CO, April 11, 2022 ? Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung dis
March 31, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 31, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 14, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
March 14, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc.
March 14, 2022	EX-99.1	Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale L Exhibit 99.1 Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat NGS? Test in January 2022 Conference Call and Webcast Today at 8:30 a.m. ET BOULDER, CO, March 14, 2022 ? Biodesix, In
March 14, 2022	EX-10.132	Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated January 24, 2022 (incorporated by reference to Exhibit 10.13.2 to the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022). Exhibit 10.13.2 THIRD AMENDMENT TO OFFICE LEASE This Third Amendment to Office Lease (this ?Third Amendment?) is dated as of January 24, 2022, by and between Aero-Tech Investments, LLC, a Colorado limited liability company (?Landlord?), and Biodesix, Inc., a Delaware corporation (?Tenant?). Recitals A. Landlord and Tenant entered into that certain Office Lease dated as of October 5, 2011, as amend
March 7, 2022	EX-10.1	Purchase Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022). Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the "Agreement"), dated as of March 7, 2022, is made by and between BIODESIX, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the "Investor"). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the I
March 7, 2022	424B5	$50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-261095 PROSPECTUS SUPPLEMENT $50,000,000 Common Stock This prospectus supplement and the accompanying prospectus relate to the issuance and sale of up to $50.
March 7, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I
March 7, 2022	EX-99.1	Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital Exhibit 99.1 Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital BOULDER, CO, March 7, 2022 ? Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million wit
March 7, 2022	EX-10.2	Registration Rights Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022). REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of March 7, 2022, is entered into by and between BIODESIX, INC.
February 14, 2022	EX-99.1	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (unaudited) Core lung diagnostic testing revenues grow 49% for full-year 2021 Exhibit 99.1 Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (unaudited) Core lung diagnostic testing revenues grow 49% for full-year 2021 Boulder, CO, February 14, 2022- Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report fourth quarter and record full-year 2021 p
February 14, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
February 14, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2022 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
February 14, 2022	EX-99.1	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (unaudited) Core lung diagnostic testing revenues grow 49% for full-year 2021 Exhibit 99.1 Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (unaudited) Core lung diagnostic testing revenues grow 49% for full-year 2021 Boulder, CO, February 14, 2022- Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report fourth quarter and record full-year 2021 p
January 28, 2022	SC 13D/A	BDSX / Biodesix Inc / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, Address and Telephone Number
January 10, 2022	SC 13G/A	BDSX / Biodesix Inc / PATIENCE JOHN - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which
January 10, 2022	SC 13G	BDSX / Biodesix Inc / PATIENCE JOHN - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No.)* Under the Securities Exchange Act of 1934 Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which t
January 7, 2022	SC 13G/A	BDSX / Biodesix Inc / Kennedy Lawrence T. Jr - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) Arthur McMahon, III, Esq. Taft Stettinius & Hollister LLP 425 Walnut Street, Suite 1800 Cincinnati, OH 45202 (513) 357-9607
January 4, 2022	SC 13D/A	BDSX / Biodesix Inc / SCHULER JACK W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biodesix, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09075X108 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, Address and Telephone Number
January 4, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 30, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
January 4, 2022	EX-10.40	Consent and Second Amendment to Loan and Security Agreement EXHIBIT 10.40 CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of December 31, 2021, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and BIODESIX, INC., a Delaware corporation (?Borrower?). RECITALS A. Bank and Borrower have entered into that certain Loan and Secu
January 4, 2022	EX-99.1	Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $16.3 million in Common Shares Sold Under At-the-market Agreement Used to Offset Prepayment of Debt Second Amendment to $30 Million Term Loan Provid EX-99.1 3 bdsx-ex991.htm EX-99.1 Exhibit 99.1 Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $16.3 million in Common Shares Sold Under At-the-market Agreement Used to Offset Prepayment of Debt Second Amendment to $30 Million Term Loan Provides Additional Financial Flexibility for Growth BOULDER, CO, January 4, 2022 – Biodesix, Inc. (Nasdaq: BD
December 22, 2021	424B5	Up to $50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-261095 PROSPECTUS Up to $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC (?Cowen?) relating to shares of our common stock, par value $0.
December 8, 2021	EX-99.1	Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors Exhibit 99.1 Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors Boulder, CO.-(BUSINESS WIRE)-December 8, 2021 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company?s board of directors. Dr. Kayyem?s di
December 8, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 6, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
November 24, 2021	CORRESP	[Signature Page Immediately Follows] November 24, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jane Park Re: Acceleration Request for Biodesix, Inc. Registration Statement on Form S-3 (File No. 333-261095) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biodesix, Inc. (the ?Company?), hereby req
November 24, 2021	S-3/A	As filed with the Securities and Exchange Commission on November 24, 2021. Table of Contents As filed with the Securities and Exchange Commission on November 24, 2021.
November 16, 2021	EX-1.2	Sales Agreement, dated as of November 15, 2021, between the Registrant and Cowen and Company, LLC. EX-1.2 2 d213737dex12.htm EX-1.2 Exhibit 1.2 BIODESIX, INC. $50,000,000 SHARES OF COMMON STOCK SALES AGREEMENT November 15, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Biodesix, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from
November 16, 2021	S-3	Power of Attorney. S-3 1 d213737ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on November 15, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIODESIX, INC. (Exact name of registrant as specified in its charter) Delaware 20-3986492 (State or other jurisdiction of i
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC.
November 15, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
November 15, 2021	EX-99.1	Biodesix Announces Third Quarter 2021 Results and Highlights Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast T Exhibit 99.1 Biodesix Announces Third Quarter 2021 Results and Highlights Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast Today at 9:00 a.m. ET BOULDER, CO, November 15, 2021 ? Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company w
November 15, 2021	EX-10.39	Consent and First Amendment to Loan and Security Agreement, dated September 30, 2021 (incorporated by reference to Exhibit 10.39 to the Company's Form 10-Q filed with the SEC on November 15, 2021). Exhibit 10.39 CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND FIRST AMENDMENT to Loan and Security Agreement (this ?Agreement?) is entered into this 30th day of September, 2021, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and BIODESIX, INC., a Delaware corporation (?Borrower?). RECITALS A.Bank and Borrower have entered into that certain Loan an
September 9, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 9, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number
September 9, 2021	EX-99.1	This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be c Third Quarter 2021 Corporate Presentation Exhibit 99.1 This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", ?we? or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Biodesix or any of
August 23, 2021	SC 13G	BDSX / Biodesix Inc / Manlia Ltd Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIODESIX, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
August 10, 2021	EX-10.37	First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021 (incorporated by reference to Exhibit 10.37 to the Company's Form 10-Q filed with the SEC on August 10, 2021). Exhibit 10.37 FIRST AMENDMENT TO THE NON-EXCLUSIVE LICENSE AGREEMENT This first amendment (?Amendment?) is effective May 24, 2021 (?Amendment Effective Date?), and is made pursuant to the Non-Exclusive License Agreement dated August 1, 2019 (?Agreement?) by and between Bio-Rad Laboratories, Inc., having an address at 1000 Alfred Nobel Drive, Hercules, California 94547 (?Bio-Rad?) and Biodesix, Inc
August 10, 2021	EX-10.5.2	Forms of Restricted Stock Unit Award Grant Notice and Award Agreement under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.2 to the Company's Form 10-Q filed with the SEC on August 10, 2021). Exhibit 10.5.2 BIODESIX, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Biodesix, Inc. (the ?Company?), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Participant a restricted stock unit award relating to the number of restricted stock units set forth below (the ?Award?). The Aw
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
August 10, 2021	EX-99.1	Biodesix Announces Second Quarter 2021 Results and Highlights Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acceleration of the Launch of the Exhibit 99.1 Biodesix Announces Second Quarter 2021 Results and Highlights Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acceleration of the Launch of the 72-hour liquid NGS Test to Early First Quarter 2022 Conference Call and Webcast Today at 4:30 p.m. ET BOULDER, CO, August 10, 2021 ? Bio
August 10, 2021	EX-10.38	Amendment No. 2 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.38 to the Company's Form 10-Q filed with the SEC on August 10, 2021). Exhibit 10.38 AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATION This Amendment No. 2 to Asset Purchase Agreement and Plan of Reorganization (this ?Amendment?), is made and entered into as of August 9, 2021, and amends that certain Asset Purchase Agreement and Plan of Reorganization, dated June 30, 2018, by and among Biodesix, Inc. (the ?Company?); Integrated Diagnostics, Inc.
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC.
May 28, 2021	SC 13G	BDSX / Biodesix Inc / Life Sciences Alternative Funding LLC - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Biodesix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075X108
May 28, 2021	EX-99	Joint Filing Agreement. Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G.
May 27, 2021	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number)
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC.
May 11, 2021	EX-99.1	Biodesix Announces First Quarter 2021 Results First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020 Announced Plans to Launch Two New Diagnostic Tests - SARS-CoV-2 Neutralization Antibody De Exhibit 99.1 Biodesix Announces First Quarter 2021 Results First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020 Announced Plans to Launch Two New Diagnostic Tests - SARS-CoV-2 Neutralization Antibody Detection Test and Next Generation Sequencing Test BOULDER, CO, May 11, 2021 ? Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnos
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (I.
April 29, 2021	DEF 14A	Definitive Proxy Statement on Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 23, 2021	EX-99.1	Biodesix Announces Closing of New $30 Million Term Loan Increases Company’s Net Liquidity Position and Reduces Near-Term Cash Interest Costs Exhibit 99.1 Biodesix Announces Closing of New $30 Million Term Loan Increases Company?s Net Liquidity Position and Reduces Near-Term Cash Interest Costs Boulder, CO, March 23, 2021- Biodesix, Inc. (NASDAQ: BDSX; ?Biodesix? or the ?Company?) a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that it has closed on a new $30 million term loan (New Term L
March 23, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
March 23, 2021	EX-10.1	Loan and Security Agreement, dated March 19, 2021 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 23, 2021). Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this ?Agreement?) dated and effective as of March 19, 2021 (the ?Effective Date?) by and between SILICON VALLEY BANK, a California corporation (?Bank?), BIODESIX, INC., a Delaware corporation (?Borrower?), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows: 1A
March 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 16, 2021 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39659 20-3986492 (State or other jurisdiction of incorporation) (Commission File Number) (
March 16, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc.
March 16, 2021	EX-4.5	Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Company's Form 10-K filed with the SEC on March 16, 2021). Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following summary describes the capital stock of Biodesix, Inc., (the ?Company,? ?we,? ?us,? and ?our?) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated regis
March 16, 2021	EX-10.5.1	Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.1 to the Company's Form 10-K filed with the SEC on March 16, 2021). Exhibit 10.5.1 BIODESIX, INC. STOCK OPTION GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Biodesix, Inc. (the ?Company?), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Optionholder an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). The Option is subject to all of the
March 16, 2021	EX-99.1	Biodesix Announces Fourth Quarter and Full Year 2020 Results Full Year 2020 Revenue Growth of 86% on Record Revenue of approximately $46 million Exhibit 99.1 Biodesix Announces Fourth Quarter and Full Year 2020 Results Full Year 2020 Revenue Growth of 86% on Record Revenue of approximately $46 million Boulder, CO, March 16, 2021- Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full year ended December 31
January 8, 2021	EX-99.2	This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be c EX-99.2 3 bdsx-ex99246.htm EX-99.2 JANUARY 2021 Corporate Presentation Exhibit 99.2 This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the pr

BDSX / Biodesix, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)